The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)
Abstract
AIMS: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. METHODS AND RESULTS: Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) or placebo were administered intravenously for 6h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0.319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2.0% vs 5.9%; P=0.033) and over 24h (4.0% vs 8.8%; P=0.044). Mortality was lower with levosimendan compared with placebo at 14 days (11.7% vs 19.6%; hazard ratio 0.56 [95% CI 0.33-0.95];P =0.031) and the reduction was maintained at the 180-day retrospective follow-up (22.6% vs 31.4%; 0.67 [0.45-1.00],P =0.053). CONCLUSION: s Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1) did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · The Lancet · Cited by 1,860
A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., DeMets, D. L., & White, B. G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392503 · Cited by 613
O'Connor, C. M., Gattis, W. A., Uretsky, B. F., Adams, K. F., McNulty, S. E., Grossman, S. H., McKenna, W. J., Zannad, F., Swedberg, K., Gheorghiade, M., et al. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70250-4 · Cited by 517
Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure
Slawsky, M. T., Colucci, W. S., Gottlieb, S. S., Greenberg, B. H., Haeusslein, E., Hare, J., Hutchins, S., Leier, C. V., LeJemtel, T. H., Loh, E., et al. (2000) · Circulation · doi:10.1161/01.cir.102.18.2222 · Cited by 478
Packer, M. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.25652 · Cited by 396
Yokoshiki, H., Katsube, Y., Sunagawa, M., & Sperelakis, N. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01108-4 · Cited by 299
Do “America's Best Hospitals” Perform Better for Acute Myocardial Infarction?
Chen, J., Radford, M. J., Wang, Y., Marciniak, T. A., & Krumholz, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400407 · Cited by 266
Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation
Haikala, H., Nissinen, E., Etemadzadeh, E., Levijoki, J. M., & Lindén, I. (1995) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199505000-00016 · Cited by 224
Yokoshiki, H., Katsube, Y., Sunagawa, M., & Sperelakis, N. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36997-6 · Cited by 179
Cited by
Mebazaa, A., Nieminen, M. S., Packer, M., Cohen-Solal, A., Kleber, F. X., Pocock, S. J., Thakkar, R., Padley, R. J., Põder, P., Kivikko, M., et al. (2007) · JAMA · doi:10.1001/jama.297.17.1883 · Cited by 994
Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease
Overgaard, C. B., & Džavík, V. (2008) · Circulation · doi:10.1161/circulationaha.107.728840 · Cited by 516
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
Dünser, M. W., & Hasibeder, W. R. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609340519 · Cited by 488
Packer, M., Colucci, W., Fisher, L., Massie, B. M., Teerlink, J. R., Young, J., Padley, R. J., Thakkar, R., Delgado-Herrera, L., Salon, J., et al. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.12.004 · Cited by 436
McMurray, J. J. V., Teerlink, J. R., Cotter, G., Bourge, R. C., Cleland, J. G. F., Jondeau, G., Krum, H., Metra, M., O’Connor, C. M., Parker, J. D., et al. (2007) · JAMA · doi:10.1001/jama.298.17.2009 · Cited by 360
Cleland, J. G. F., Freemantle, N., Coletta, A. P., & Clark, A. L. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.12.003 · Cited by 320
Levosimendan: Molecular mechanisms and clinical implications
Papp, Z., Édes, I., Fruhwald, S., De Hert, S. G., Salmenperä, M., Leppikangas, H., Mebazaa, A., Landoni, G., Grossini, E., Caimmi, P., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.022 · Cited by 319
Mebazaa, A., Gheorghiade, M., Piña, I. L., Harjola, V.-P., Hollenberg, S. M., Follath, F., Rhodes, A., Plaisance, P., Roland, E., Nieminen, M., et al. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0000296274.51933.4c · Cited by 279
Sustained Hemodynamic Effects of Intravenous Levosimendan
Kivikko, M., Lehtonen, L., & Colucci, W. S. (2003) · Circulation · doi:10.1161/01.cir.0000043245.00859.11 · Cited by 258
Hummel, J., Rücker, G., & Stiller, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011312.pub3 · Cited by 40
Metadata
- Authors
- Moiseyev, V
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-09-15
- Volume
- 23
- Issue
- 18
- Pages
- 1422-1432
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2117483856
- Cited by
- 595
- References
- 21
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.